Literature DB >> 33765054

Impact of adenosine on mechanisms sustaining persistent atrial fibrillation: Analysis of contact electrograms and non-invasive ECGI mapping data.

Gurpreet Singh Dhillon1, Nikhil Ahluwalia1, Shohreh Honarbakhsh1, Adam Graham1, Antonio Creta1, Hakam Abbass1, Anthony Chow1, Mark J Earley1, Pier D Lambiase1, Richard J Schilling1, Ross J Hunter1.   

Abstract

BACKGROUND: We evaluated the effect of adenosine upon mechanisms sustaining persistent AF through analysis of contact electrograms and ECGI mapping.
METHODS: Persistent AF patients undergoing catheter ablation were included. ECGI maps and cycle length (CL) measurements were recorded in the left and right atrial appendages and repeated following boluses of 18 mg of intravenous adenosine. Potential drivers (PDs) were defined as focal or rotational activations completing ≥ 1.5 revolutions. Distribution of PDs was assessed using an 18 segment biatrial model.
RESULTS: 46 patients were enrolled. Mean age was 63.4 ± 9.8 years with 33 (72%) being male. There was no significant difference in the number of PDs recorded at baseline compared to adenosine (42.1 ± 15.2 vs 40.4 ± 13.0; p = 0.417), nor in the number of segments harbouring PDs, (13 (11-14) vs 12 (10-14); p = 0.169). There was a significantly higher percentage of PDs that were focal in the adenosine maps (36.2 ± 15.2 vs 32.2 ± 14.4; p < 0.001). There was a significant shortening of CL in the adenosine maps compared to baseline which was more marked in the right atrium than left atrium (176.7 ± 34.7 vs 149.9 ± 27.7 ms; p < 0.001 and 165.6 ± 31.7 vs 148.3 ± 28.4 ms; p = 0.003).
CONCLUSION: Adenosine led to a small but significant shortening of CL which was more marked in the right than left atrium and may relate to shortening of refractory periods rather than an increase in driver burden or distribution. Registered on Clinicaltrials.gov: NCT03394404.

Entities:  

Year:  2021        PMID: 33765054      PMCID: PMC7993562          DOI: 10.1371/journal.pone.0248951

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  18 in total

1.  Administration of isoproterenol and adenosine to guide supplemental ablation after pulmonary vein antrum isolation.

Authors:  Claude S Elayi; Luigi Di Biase; Rong Bai; J David Burkhardt; Prasant Mohanty; Pasquale Santangeli; Javier Sanchez; Richard Hongo; G Joseph Gallinghouse; Rodney Horton; Shane Bailey; Salwa Beheiry; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2013-09-10

2.  Adenosine-induced atrial fibrillation: insights into mechanism.

Authors:  James E Ip; Jim W Cheung; Jeffrey H Chung; Christopher F Liu; George Thomas; Steven M Markowitz; Bruce B Lerman
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-06

3.  Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.

Authors:  Franz Faul; Edgar Erdfelder; Axel Buchner; Albert-Georg Lang
Journal:  Behav Res Methods       Date:  2009-11

4.  Driver domains in persistent atrial fibrillation.

Authors:  Michel Haissaguerre; Meleze Hocini; Arnaud Denis; Ashok J Shah; Yuki Komatsu; Seigo Yamashita; Matthew Daly; Sana Amraoui; Stephan Zellerhoff; Marie-Quitterie Picat; Adam Quotb; Laurence Jesel; Han Lim; Sylvain Ploux; Pierre Bordachar; Guillaume Attuel; Valentin Meillet; Philippe Ritter; Nicolas Derval; Frederic Sacher; Olivier Bernus; Hubert Cochet; Pierre Jais; Remi Dubois
Journal:  Circulation       Date:  2014-07-15       Impact factor: 29.690

5.  Differential effects of adenosine on pulmonary vein ectopy after pulmonary vein isolation: implications for arrhythmogenesis.

Authors:  Jim W Cheung; James E Ip; Jeffrey H Chung; Steven M Markowitz; Christopher F Liu; George Thomas; Joseph M Lee; Seth J Lessner; Bruce B Lerman
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-06-23

6.  Right-to-left frequency gradient during atrial fibrillation initiated by right atrial ectopies and its augmentation by adenosine triphosphate: Implications of right atrial fibrillation.

Authors:  Hideyuki Hasebe; Kentaro Yoshida; Masataka Iida; Naoki Hatano; Toshiro Muramatsu; Kazutaka Aonuma
Journal:  Heart Rhythm       Date:  2015-09-30       Impact factor: 6.343

7.  Complexity and Distribution of Drivers in Relation to Duration of Persistent Atrial Fibrillation.

Authors:  Han S Lim; Mélèze Hocini; Remi Dubois; Arnaud Denis; Nicolas Derval; Stephan Zellerhoff; Seigo Yamashita; Benjamin Berte; Saagar Mahida; Yuki Komatsu; Matthew Daly; Laurence Jesel; Carole Pomier; Valentin Meillet; Sana Amraoui; Ashok J Shah; Hubert Cochet; Frédéric Sacher; Pierre Jaïs; Michel Haïssaguerre
Journal:  J Am Coll Cardiol       Date:  2017-03-14       Impact factor: 24.094

8.  Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial.

Authors:  Laurent Macle; Paul Khairy; Rukshen Weerasooriya; Paul Novak; Atul Verma; Stephan Willems; Thomas Arentz; Isabel Deisenhofer; George Veenhuyzen; Christophe Scavée; Pierre Jaïs; Helmut Puererfellner; Sylvie Levesque; Jason G Andrade; Lena Rivard; Peter G Guerra; Marc Dubuc; Bernard Thibault; Mario Talajic; Denis Roy; Stanley Nattel
Journal:  Lancet       Date:  2015-07-23       Impact factor: 79.321

9.  Adenosine-induced pulmonary vein ectopy as a predictor of recurrent atrial fibrillation after pulmonary vein isolation.

Authors:  Jim W Cheung; Frank S Lin; James E Ip; Seth R Bender; Faisal K Siddiqi; Christopher F Liu; George Thomas; Steven M Markowitz; Bruce B Lerman
Journal:  Circ Arrhythm Electrophysiol       Date:  2013-11-15

10.  Multicentre evaluation of non-invasive biatrial mapping for persistent atrial fibrillation ablation: the AFACART study.

Authors:  Sébastien Knecht; Manav Sohal; Isabelle Deisenhofer; Jean-Paul Albenque; Thomas Arentz; Thomas Neumann; Bruno Cauchemez; Mattias Duytschaever; Khaled Ramoul; Thierry Verbeet; Sonia Thorsten; Amir Jadidi; Stephane Combes; René Tavernier; Yves Vandekerckhove; Sabine Ernst; Douglas Packer; Thomas Rostock
Journal:  Europace       Date:  2017-08-01       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.